From the Department of Radiation Oncology and Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
Molecular Imaging Branch, Radiation Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD.
Cancer J. 2024;30(3):218-223. doi: 10.1097/PPO.0000000000000720.
Radiopharmaceutical therapy has emerged as a promising approach for the treatment of various cancers. The exploration of novel targets such as tumor-specific antigens, overexpressed receptors, and intracellular biomolecules using antibodies, peptides, or small molecules has expanded the scope of radiopharmaceutical therapy, enabling precise and effective cancer treatment for an increasing number of tumor types. Alpha emitters, characterized by their high linear energy transfer and short path length, offer unique advantages in targeted therapy due to their potent cytotoxicity against cancer cells while sparing healthy tissues. This article reviews recent advancements in identifying novel targets for radiopharmaceutical therapy and applications in utilizing α-emitters for targeted treatment.
放射性药物治疗已成为治疗各种癌症的一种有前途的方法。利用抗体、肽或小分子探索肿瘤特异性抗原、过表达受体和细胞内生物分子等新型靶点,扩大了放射性药物治疗的范围,使越来越多的肿瘤类型能够进行精确和有效的癌症治疗。α发射器具有高线性能量传递和短路径长度的特点,由于其对癌细胞的强大细胞毒性而对健康组织的损伤较小,因此在靶向治疗中具有独特的优势。本文综述了放射性药物治疗中新型靶点的鉴定和利用α发射器进行靶向治疗的最新进展。